Top section
Top section
I thought the grass would be greener in fintech land, but it’s patchy and dreary
Hybrid capital is open to the big US tech companies. But who needs an umbrella when the sun is shining?
Years of underperformance are behind it and the bank has launched a new growth plan
More articles
More articles
More articles
-
CapVest has cancelled the planned sale of Curium Pharma, as market conditions wrecked the investment appetite of the three final round bidders and banks cut financing commitments. It was one of the larger M&A financings slated for syndication in the second quarter, but with the Crossover index now trading over 650bp, compared with close to 200bp when first round bids were due, the three sponsors in the final round would have struggled to get a deal away. -
The wild daily swings in equity markets and stratospheric levels of volatility caused by the Covid-19 crisis has left equity capital markets bankers with very little to do, beyond waiting for the market to find a floor when executing transactions becomes feasible once again.
-
Shanghai Titan Scientific, Speechocean and Easton Biopharmaceuticals are all planning to make a second attempt at listing on Shanghai’s Star market.
-
David Binnion, co-head of equity capital markets for Asia ex-Japan at Goldman Sachs, is retiring after 15 years at the firm, according to a memo seen by GlobalCapital Asia.
-
Chinese e-commerce giant JD.com has hired Bank of America and UBS to lead a secondary listing in Hong Kong, according to multiple sources familiar with the matter.
-
Sasol, the South African chemicals company, has unveiled a $6bn package of measures designed to shore up its business, which has been damaged by the spread of the Covid-19 virus and the collapse in oil prices.
Sub-sections
shared comment list
